GlobalData on MSN
Takeda’s oral TYK2 blocker outperforms Sotyktu in PsA trial
Based on this data and data from two other Phase III trials, Takeda will file for the approval of zasocitinib in PsA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results